Latest News - Oklahoma Society of Clinical Oncology

Merck’s WELIREG™ (belzutifan) Receives FDA Approval

Merck has informed OSCO that WELIREG™ (belzutifan) 40-mg tablets has received FDA approval. WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. SELECTED SAFETY INFORMATION WARNING: EMBRYO-FETAL […]

Read More

Natera’s Signatera® Selected for US Trial

Natera is proud to announce that Signatera has been selected for NRG Oncology pivotal CIRCULATE – US trial for patients with resected stage II or III colon cancer. CIRCULATE -US (NRG-G1008) is a prospective, multi-center, randomized clinical trial that aims to establish a new standard of care (SOC) for these patients using Signatera MRD to guide […]

Read More

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia

BeiGene Ltd. Announces a new approval for BRUKINSA (zanubrutinib) in Waldenström’s macroglobulinaemia, including the updated Prescribing Information. For more information: Download BRUKINSA Full Prescribing Information Download BRUKINSA Patient Information BRUKINSA WEBSITE

Read More

Pfizer Vaccines US Medical Affairs hosting Informational sessions on COMIRNATY®.

The Pfizer Vaccines US Medical Affairs team will be hosting “Medical Updates:  Pfizer-BioNTech COVID-19 Vaccine, also known as COMIRNATY® (COVID-19 Vaccine, mRNA),” on Tuesdays, at 5pm ET and Thursday’s at 12pm ET for the remainder of 2021.    These sessions will be continuously updated to reflect new information and changes that evolve.  Such updates will be identified at the start of each session and further […]

Read More

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

On 8/20/21 Bristol Myers Squibb announced that Opdivo®(nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior […]

Read More

Permanent J-Code Assigned for Pepaxto® (melphalan flufenamide)

INDICATION:   PEPAXTO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication is approved under […]

Read More

Clinical Trial Support Center Available to Connect Patients with Blood Cancer to Clinical Trials

ASH and The Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center (CTSC) have collaborated to enhance access to LLS’s free service providing clinical trials navigation and support to health care professionals, and patients with blood cancer and their families. ASH member physicians and their care teams, along with patients and caregivers, receive one-on-one support […]

Read More

KEYTRUDA® receives additional FDA approval

The FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Recommended Dosage for High-Risk Early-Stage TNBC Please refer to the Prescribing Information for KEYTRUDA for information […]

Read More

New ASCO-COA Oncology Medical Home Standards Set High Bar, Offers Roadmap for Comprehensive High-Quality, Patient-Centered Cancer Care Delivery 

On July 13, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards to provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence based cancer care. By releasing the new standards, ASCO and COA seek to achieve a broad consensus among all […]

Read More

Oncopeptides announces that PEPAXTO® is now included in the NCCN Clinical Practice Guidelines.

Melphalan Flufenamide (PEPAXTO®) is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 6.2021 – April 12, 2021 Category 2A1 Definitions for National Comprehensive Cancer Network® (NCCN®) Categories:   Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.   For more […]

Read More